Daniela Bianconi

A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid

Markus Kieler, Matthias Unseld, Daniela Bianconi et al. · Therapeutic Advances in Medical Oncology · 2019 · 48 citations · Full text

Medicine, Oncology, Pharmacology +16

Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients

Markus Kieler, Matthias Unseld, Daniela Bianconi et al. · Journal of Clinical Medicine · 2020 · 34 citations · Full text

Medicine, Oncology, Pharmacology +15

Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC

Daniela Bianconi, Merima Herac, Florian Posch et al. · Therapeutic Advances in Medical Oncology · 2020 · 23 citations · Full text

Medicine, Oncology, Pharmacology +17

Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients

Daniela Bianconi, Alexandra Schuler, Clemens Pausz et al. · Thrombosis Research · 2015 · 22 citations · Full text

Medicine, Genetics, Oncology +17

Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy

Markus Kieler, Matthias Unseld, Johann Wojta et al. · Medical Oncology · 2018 · 20 citations · Full text

Medicine, Immunology, Oncology +17